Minerva Neurosciences Equity 2024

Minerva Neurosciences Aktienanalyse

What does Minerva Neurosciences do?

Minerva Neurosciences was founded in 2007 and is a biopharmaceutical company focused on developing therapies for various psychiatric and neurological disorders. The company's business model is based on identifying promising molecules and developing them clinically until they are approved by health authorities. Minerva works closely with academic institutions and other partners to expand its pipeline of potential products. The company is focused on developing therapies for disorders such as schizophrenia, depression, sleep disorders, Parkinson's, and Alzheimer's. Minerva Neurosciences' main products are the antipsychotic MIN-101, targeting the treatment of schizophrenia, and the antidepressant MIN-117, developed for the treatment of depression. Both products are currently in clinical development and have the potential to offer new treatment options for patients. Furthermore, Minerva Neurosciences has entered into exclusive licensing agreements with other companies to develop innovative therapies for rare diseases. One of these products is the medication Roluperidone, which can be used for schizophrenic disorders. Minerva Neurosciences is divided into three business segments: Minerva Neurosciences Inc, Minerva Manufacturing Inc, and Minerva Therapeutics Inc. Minerva Manufacturing has its own research and development department and specializes in manufacturing clinical trial products. Minerva Therapeutics is a subsidiary focused on developing gene therapies for rare diseases. The company aims to improve the quality of life for patients with neurological and psychiatric disorders. Minerva Neurosciences pursues a strategy of collaborating with external partners and academic institutions to foster innovation and develop new therapies. Overall, Minerva Neurosciences has the potential to play a significant role in the treatment of central nervous system disorders and improve the health and well-being of millions of people worldwide. Minerva Neurosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Minerva Neurosciences's Equity

Minerva Neurosciences's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Minerva Neurosciences's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Minerva Neurosciences's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Minerva Neurosciences's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Minerva Neurosciences’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Minerva Neurosciences Stock

What is the equity of Minerva Neurosciences this year?

Minerva Neurosciences has equity of -28.46 M USD this year.

What was the equity of Minerva Neurosciences compared to the previous year?

The equity of Minerva Neurosciences has increased/decreased by 42.29% increased compared to the previous year.

What impact does a high equity have on investors of Minerva Neurosciences?

A high equity is advantageous for investors of Minerva Neurosciences as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Minerva Neurosciences?

A low equity can be a risk for investors of Minerva Neurosciences, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Minerva Neurosciences affect the company?

An increase in equity of Minerva Neurosciences can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Minerva Neurosciences affect the company?

A reduction in equity of Minerva Neurosciences can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Minerva Neurosciences?

Some factors that can affect the equity of Minerva Neurosciences include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Minerva Neurosciences so important for investors?

The equity of Minerva Neurosciences is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Minerva Neurosciences take to change the equity?

To change equity, Minerva Neurosciences can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Minerva Neurosciences pay?

Over the past 12 months, Minerva Neurosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Minerva Neurosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Minerva Neurosciences?

The current dividend yield of Minerva Neurosciences is .

When does Minerva Neurosciences pay dividends?

Minerva Neurosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Minerva Neurosciences?

Minerva Neurosciences paid dividends every year for the past 0 years.

What is the dividend of Minerva Neurosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Minerva Neurosciences located?

Minerva Neurosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Minerva Neurosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Minerva Neurosciences from 6/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/30/2024.

When did Minerva Neurosciences pay the last dividend?

The last dividend was paid out on 6/30/2024.

What was the dividend of Minerva Neurosciences in the year 2023?

In the year 2023, Minerva Neurosciences distributed 0 USD as dividends.

In which currency does Minerva Neurosciences pay out the dividend?

The dividends of Minerva Neurosciences are distributed in USD.